Bevacizumab Combined With Double Doses of Icotinib in Advanced NSCLC Patients With EGFR L858R Mutation
Tianjin Medical University Cancer Institute and Hospital
Tianjin Medical University Cancer Institute and Hospital
Sun Yat-sen University
Betta Pharmaceuticals Co., Ltd.
Betta Pharmaceuticals Co., Ltd.
Peking University Cancer Hospital & Institute
Betta Pharmaceuticals Co., Ltd.
Liaoning Cancer Hospital & Institute
Peking University Cancer Hospital & Institute
Betta Pharmaceuticals Co., Ltd.
Tianjin Medical University Cancer Institute and Hospital
Tianjin Medical University Cancer Institute and Hospital
Betta Pharmaceuticals Co., Ltd.
Nanfang Hospital, Southern Medical University
Betta Pharmaceuticals Co., Ltd.
Betta Pharmaceuticals Co., Ltd.
Betta Pharmaceuticals Co., Ltd.
China Medical University, China
Guangdong Association of Clinical Trials
ChineseAMS
ChineseAMS
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Hangzhou Cancer Hospital
Qilu Hospital of Shandong University
Betta Pharmaceuticals Co., Ltd.
Betta Pharmaceuticals Co., Ltd.
Betta Pharmaceuticals Co., Ltd.
Betta Pharmaceuticals Co., Ltd.
Betta Pharmaceuticals Co., Ltd.
Betta Pharmaceuticals Co., Ltd.
Betta Pharmaceuticals Co., Ltd.
Betta Pharmaceuticals Co., Ltd.
Betta Pharmaceuticals Co., Ltd.
Nanfang Hospital, Southern Medical University
People's Hospital of Guangxi Zhuang Autonomous Region
Betta Pharmaceuticals Co., Ltd.
Shandong Cancer Hospital and Institute
Zhejiang Cancer Hospital
Betta Pharmaceuticals Co., Ltd.
Betta Pharmaceuticals Co., Ltd.
Betta Pharmaceuticals Co., Ltd.
Zhejiang Cancer Hospital